Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Feasibility of a Home-Based Cognitive-Physical Exercise Program in Chronic Obstructive Pulmonary Disease (COPD) Patients: A Pilot Randomized Controlled Trial
Cognitive and physical function impairments are common in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Research has shown that cognitive and physical exercise training may be a beneficial strategy to improve physical and cognitive performance in COPD patients; however, interventions combining physical and cognitive training have not been evaluated in this population. The objectives of this research are i) to evaluate the feasibility of an 8-week home-based cognitive-physical training program in COPD patients; and ii) to derive preliminary estimates on intervention efficacy with cognitive-physical training on dual-task performance, physical function, activities of daily living, and health-related quality of life. Related to our research objectives, we hypothesize that i) it will be feasible to safely recruit COPD patients into a home-based cognitive physical training program with 75% adherence and high satisfaction ratings with the prescribed training; and that ii) the combination of cognitive and physical training will be superior to physical training alone for improving dual-task and cognitive performance, physical function, activities of daily living, and health-related quality of life.
Status | Recruiting |
Enrollment | 24 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Adult participants (= 50 years of age) - Clinical and spirometric diagnosis of COPD (FEV1 30-80%) - Access to reliable internet connection - Ability to mobilize independently and safely, with or without a walking aid Exclusion Criteria: - Current participation in a pulmonary rehabilitation program - Disease exacerbation in the past 3 months - Diagnosis of a neurological or musculoskeletal condition that would interfere with safe performance of study tests (e.g., stroke, myopathy, inflammatory arthritis) - Severe cognitive impairment ascertained by chart review or self-reported - Coronary artery disease, pacemaker or implantable defibrillator, clinical diagnosis of congestive heart failure (CHF), or poorly controlled arrhythmias - Medical instability (hepatic dysfunction, metabolic abnormalities, or active infection) - Overt psychiatric disorder or substance abuse - Patient on home oxygen therapy - Insufficient English fluency and cognition to carry out testing and training - Patient actively listed for lung transplantation |
Country | Name | City | State |
---|---|---|---|
Canada | University Health Network | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto | Boehringer Ingelheim, Canadian Institutes of Health Research (CIHR) |
Canada,
Behnke M, Taube C, Kirsten D, Lehnigk B, Jorres RA, Magnussen H. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir Med. 2000 Dec;94(12):1184-91. doi: 10.1053/rmed.2000.0949. — View Citation
Higbee DH, Dodd JW. Cognitive impairment in COPD: an often overlooked co-morbidity. Expert Rev Respir Med. 2021 Jan;15(1):9-11. doi: 10.1080/17476348.2020.1811090. Epub 2020 Aug 26. No abstract available. — View Citation
Holland AE, Mahal A, Hill CJ, Lee AL, Burge AT, Cox NS, Moore R, Nicolson C, O'Halloran P, Lahham A, Gillies R, McDonald CF. Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial. Thorax. 2017 Jan;72(1):57-65. doi: 10.1136/thoraxjnl-2016-208514. Epub 2016 Sep 26. — View Citation
Hung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Jul 15;180(2):134-7. doi: 10.1164/rccm.200902-0276OC. Epub 2009 May 7. — View Citation
Torres-Sanchez I, Rodriguez-Alzueta E, Cabrera-Martos I, Lopez-Torres I, Moreno-Ramirez MP, Valenza MC. Cognitive impairment in COPD: a systematic review. J Bras Pneumol. 2015 Mar-Apr;41(2):182-90. doi: 10.1590/S1806-37132015000004424. Epub 2015 Apr 18. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Study Recruitment | Recruitment-success percentage and reasons for participation/non-participation in the study will be collected. A consent rate of 30% or greater has been established as our criteria to determine study feasibility for future projects. | Over the study period (8 weeks) | |
Primary | Participant Retention in the Study | Participant retention will be assessed by measuring participant follow-up with testing throughout the study period. A retention rate of 80% or greater (in each group) has been established as our criteria to determine study feasibility. | Over the study period (8 weeks) | |
Primary | Adherence to Physical Training | Adherence to the exercise training intervention will be expressed as the percentage of physical exercise activities/training days completed out of the total number of activities/training days prescribed. Adherence to the exercise intervention of 75% or greater has been established as our criteria to determine feasibility for future projects. | Over the intervention period (8 weeks) | |
Primary | Adherence to Cognitive Training | Adherence to the cognitive training intervention will be expressed as i) the number of cognitive training days completed out of the total number of cognitive training days prescribed, and ii) the number of cognitive training levels and minutes completed out of the number of levels and minutes prescribed using the Brain HQ platform. Adherence to the cognitive training of 75% or greater has been established as our criteria to determine study feasibility. | Over the intervention period (8 weeks) | |
Primary | Safety and Tolerability of Cognitive and Physical Training | Any adverse events with physical training will be assessed throughout the study period. | Over the intervention period (8 weeks) | |
Primary | Participant Satisfaction with the Cognitive and Physical Training Interventions | A multiple-choice and free-form questionnaire assessing the participants' satisfaction with the cognitive and physical training programs will be completed by study participants. | Change from baseline at weeks 1, 4 and 8 | |
Secondary | Cognitive Function | The Montreal Cognitive Assessment (MoCA) will be used to screen for cognitive impairment, specifically short-term memory, visuospatial abilities, executive functions, attention, concentration, working memory, language, and orientation to time and place. The MoCA will be administered at the baseline assessment only to help characterize our study population and it takes around 10 minutes to be completed. | Baseline | |
Secondary | Physical Activity Levels | The International Physical Activity Questionnaire - Short Form (IPAQ-SF) will be used to measure physical activity levels in study participants. The questionnaire consists of seven questions to capture average daily time spent sitting, walking, and engaging in moderate and vigorous physical activity over the last seven days. The IPAQ-SF provides an overall physical activity level of participants based on their Metabolic Equivalent Task minutes (MET-min) per week. | Baseline | |
Secondary | Demographics Information | A demographic questionnaire will be administered to collect information on age, sex, ethnicity, employment status, education level, and smoking history. | Baseline | |
Secondary | Dual Task Performance | Study participants will be asked to complete two single tasks and a dual-task: i) spelling backwards: spelling five letter words backwards from a list of 100 words for one minute; ii) motor task: pedaling on a foot peddler for 1 minute at a set speed of 50 RPM and at a self-selected resistance that will allow participants to hold a conversation; iii) dual-task: pedaling for 1 minute at a speed targeting 50 RPM while spelling five letter words backwards from a list of 100 words. | Change from baseline at 4 and 8 weeks | |
Secondary | Cognitive Performance | Participants will have their progress evaluated with cognitive training using the BrainHQ platform. BrainHQ assessments measure how the participants' performance changes and evaluate the success of the cognitive training program. Testing assignments will be personalized by using the Personal Trainer option and will have a focus on evaluating sustained attention, executive function, short and long-term memory, and anxiety and depression. | Change from baseline at 4 and 8 weeks | |
Secondary | Physical Function | The short physical performance battery (SPPB) will be used to assess balance, gait, lower extremity strength, and endurance. This assessment evaluates the participants' ability to stand with their feet together in several positions (side-by-side, semi-tandem, and tandem), walking speed over 4 meters, and chair stands (time to rise from a chair and return to the seated position five times). | Change from baseline at 4 and 8 weeks | |
Secondary | Aerobic Endurance | Aerobic endurance will be measured via a foot peddler test developed by our research group. Participants will be instructed to sit on a standard chair and to pedal at a self-selected speed for 2 minutes. After warming up, participants will continue pedaling at 50 revolutions per minute at a Borg Exertion intensity of 4. Participants will be instructed to continue pedaling for as long as they are able to maintain the current exertional intensity. | Change from baseline at 4 and 8 weeks | |
Secondary | Severity of Dyspnea | The Medical Research Council (MRC) Dyspnea Scale (scores 1 to 5) will be used to assess the effect of breathlessness on daily activities. | Change from baseline at 4 and 8 weeks | |
Secondary | Exertional Dyspnea and Leg Fatigue | The highest score on a 10-point Borg Dyspnea scale at the start and end of the Aerobic Endurance (foot peddler) test will be the primary dyspnea and leg fatigue measure. | Change from baseline at 4 and 8 weeks | |
Secondary | Qualitative Descriptors of Dyspnea | The 18-point Qualitative Dyspnea Scale will be ascertained at baseline and at the end of the Aerobic Endurance (foot peddler) test from a list of 18 descriptors. | Change from baseline at 4 and 8 weeks | |
Secondary | Lower Body Strength | The one-minute sit-to-stand test (1-STS) will be performed to evaluate lower body strength using a standard chair (46 cm). Participants will stand upright and without delay sit down again, repeating the procedure as many times as possible in a 1 min period. Participants will be instructed to indicate their Borg Dyspnea and Borg Leg Exertion scores before and after the test. | Change from baseline at 4 and 8 weeks | |
Secondary | Physical Activity | Physical activity will be measured via an activity tracker (Fitbit, San Francisco, USA) which will record daily activity levels (minutes and steps) of the study participants. | 7-day intervals at week 1, week 4, and week 8 | |
Secondary | Exercise Training | Exercise behaviours of the study participants will be collected via a self-reported exercise log. These logs will comprise of sections in which participants must describe the type of exercise, duration/repetitions, and intensity. | Daily over the intervention period (8 weeks) | |
Secondary | Disease Specific Quality of Life | The St. George's Respiratory Questionnaire will be administered to measure the impact of COPD on overall health, daily life, and perceived well-being in our cohort. The questionnaire is composed of 50 items with scores ranging from 0 to 100 (higher scores indicate more limitations). | Change from baseline at 4 and 8 weeks | |
Secondary | Impact of Symptoms on COPD | The COPD Assessment Test (CAT) will be implemented to assess cough, production of phlegm, chest tightness, breathlessness, activity limitation, confidence, sleep, and energy. The CAT consists of eight items, each formatted as a six-point differential scale and with an overall score ranging from 0 to 40. | Change from baseline at 4 and 8 weeks | |
Secondary | Limitations in Daily Activities | The London Chest Activities of Daily Living Questionnaire will be administered to assess the limitations in performing activities of daily living as a consequence of dyspnea. It is composed of 4 domains: self-care, domestic activities, physical activities, and leisure. | Change from baseline at 4 and 8 weeks | |
Secondary | Self-Efficacy to Exercise | The Exercise Self-Regulatory Efficacy Scale (Ex-SRES) will be administered to measure exercise self-regulatory efficacy. The Ex-SRES is composed of 16 items asking participants to indicate the degree to which they are confident they could continue to exercise regularly when faced with different barriers. Participants will have to indicate their confidence level from 0% (not at all confident) to 100% (highly confident). | Change from baseline at 4 and 8 weeks | |
Secondary | Mood | The Depression, Anxiety and Stress Scale (DASS-21) questionnaire has 21 items to assess mood (anxiety, depression, and stress). There are three self-report scales designed to measure the emotional states of depression, anxiety and stress with each question ranging from a score of 0 (did not apply) to 3 (applied most of the time). Scores for each domain (depression, anxiety, and stress) will be categorized as follows: Normal, Mild, Moderate, Severe, and Extremely Severe. | Change from baseline at 4 and 8 weeks | |
Secondary | Clinical Characteristics | Clinical characteristics including forced expiratory volume in the first second (FEV1), medications (e.g., opioids, prednisone), baseline 6-minute walk distance, body mass index, airway obstruction, dyspnea, and exercise capacity (BODE) index, and exacerbation history will be ascertained from chart review. | Over the intervention period (8 weeks) and one year prior to study enrollment | |
Secondary | Anthropometry | Participants will be asked to provide data on their body weight if they have access to a weight scale at home. Otherwise, the values from their most recent pulmonary function testing will be abstracted. | Change from baseline at 4 and 8 weeks | |
Secondary | Vitals | Participants will be asked to provide data on their blood pressure if they have access to a blood pressure monitor. Oxygen saturation and heart rate will be measured via a pulse oximeter. | Change from baseline at 4 and 8 weeks | |
Secondary | Health Care Utilization | Information on health care utilization (i.e., exacerbations, use of steroid/antibiotics, mortality, admissions to hospital, history of falls, and emergency department visits) will be collected with a self-reported questionnaire administered to participants and through chart review. | Over the intervention period (8 weeks) and one year prior to study enrollment | |
Secondary | Presence of Comorbidities | The presence of comorbidities in our study participants will be ascertained using the Charlson Comorbidity Index and through chart review using a comprehensive comorbidity questionnaire developed by our team. | Over the intervention period (8 weeks) and one year prior to study enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|